Global Central Nervous System Disorders Therapeutics Market 2016-2020

  • ID: 3883907
  • Report
  • Region: Global
  • 147 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AB Science
  • Auspex Pharmaceuticals
  • Euthymics
  • Kyowa Hakko Kirin
  • Opexa
  • Shire
  • MORE
About CNS disorders

CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.

The analysts forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Janssen Pharmaceuticals
- Novartis

Other prominent vendors
- AB Science
- AbbVie
- Abital Pharma
- Acorda Therapeutics
- Active Biotech
- Adamas Pharmaceuticals
- Addex Therapeutics
- Akorn
- Alcobra
- Alexza Pharmaceuticals
- Alkermes
- Amarantus
- Aprecia Pharmaceuticals
- Archer Pharmaceuticals
- Astellas
- AstraZeneca
- Aurobindo Pharma
- Auspex Pharmaceuticals
- Avanir Pharmaceuticals
- Biscayne Pharmaceuticals
- Boehringer Ingelheim
- Cerecor
- Concordia
- Convergence Pharmaceuticals
- Curemark
- CURx Pharmaceuticals
- Dainippon Sumitomo Pharma
- Dart NeuroScience
- Delpor
- Desitin Arzneimittel
- D-Pharm
- Edgemont Pharmaceuticals
- Endo International
- E-Therapeutics
- Euthymics
- Evotec
- F. Hoffmann-La Roche
- Fabre-Kramer Pharmaceuticals
- Forum Pharmaceuticals
- Gedeon Richter
- Glenmark
- Grupo Ferrer Internacional
- GW Pharmaceuticals
- H. Lundbeck
- Hisamitsu
- Impax
- Insero Health
- INSYS Therapeutics
- Intellipharmaceutics
- Intra-Cellular Therapies
- Ipsen
- Kyowa Hakko Kirin
- Ligand Pharmaceuticals
- Lupin
- MarcoPolo Pharmaceuticals
- Marinus Pharmaceuticals
- Meda AB
- Merck
- Mitsubishi Tanabe
- MSI Methylation Sciences
- Mylan
- Naurex
- Neuralstem
- Neurelis
- Neurovance
- Nobelpharma
- Noven Pharmaceuticals
- Omeros
- Opexa
- Opko Health
- Orion
- Ophelia Pharmaceutical
- Otsuka Pharmaceuticals
- Palobiofarma
- Par Pharmaceuticals
- Pierre Fabre
- Prana Biotechnology
- Raptor Pharmaceutical
- Reviva Pharmaceuticals
- SAGE Therapeutics
- Sanofi
- SciFlour
- Sedor Pharmaceuticals
- Shire
- Siena Biotech
- SK Biopharmaceuticals
- SOM Biotech
- Somerset Pharmaceuticals
- STADA Arzneimittel
- Sun Pharmaceuticalc
- Sunovion Pharmaceuticals
- Supernus Pharmaceuticals
- Suven
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Tris Pharma
- Turing Pharmaceuticals
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Zinfandel Pharmaceuticals
- Zogenix

Market driversssss
- New DMD approvals for AD, PD, and MS
- For a full, detailed list, view the full report

Market challengesssss
- High failure rates of late-stage products in clinical trials
- For a full, detailed list, view the full report

Market trends
- Increased uptake of new-generation drugs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science
  • Auspex Pharmaceuticals
  • Euthymics
  • Kyowa Hakko Kirin
  • Opexa
  • Shire
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Pipeline portfolio
  • Phase III pipeline portfolio: Global CNS disorders therapeutics market
  • Phase II pipeline portfolio: Global CNS disorders therapeutics market
  • Phase I pipeline portfolio: Global CNS disorders therapeutics market
  • Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market
PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Market segmentation by type of disease
  • Global depression drugs market
  • Global MS drugs market
  • Global schizophrenia drugs market
  • Global bipolar disorder therapeutics market
  • Global AD drugs market
  • Global epilepsy drugs market
  • Global PD drugs market
PART 08: Geographical segmentation
  • CNS disorders therapeutics market in Americas
  • CNS disorders therapeutics market in EMEA
  • CNS disorders therapeutics market in APAC
PART 09: Market drivers
  • Special regulatory designations for CNS disorders
  • New DMD approvals for AD, PD, and MS
  • Development of novel therapeutics using innovative technologies
  • High growth potential of mAbs
PART 10: Impact of drivers

PART 11: Market challenges
  • High failure rates of late-stage products in clinical trials
  • Growing use of non-invasive neuromodulation and seizure management devices
  • Unavailability of standard diagnostic methods
  • Increase in rehabilitation programs
  • Social stigma associated with CNS diseases
PART 12: Impact of drivers and challenges

PART 13: Market trends
  • Popularity of me-too drugs
  • Increased uptake of new-generation drugs
  • Reformulation of marketed drugs
  • Focus on regenerative therapies for CNS disorders
  • Increase in use of LAI antipsychotics
PART 14: Vendor landscape
  • Competitive scenario
  • Key news
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Novartis
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
PART 16: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global CNS disorders therapeutics market snapshot
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Key buying criteria for CNS drugs 2015
Exhibit 05: Share of pipeline molecules in global CNS disorders therapeutics market
Exhibit 06: Prevalence of dementia in various regions (millions)
Exhibit 07: Revenues of top-selling CNS drugs (2013-2015)
Exhibit 08: Global CNS disorders therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 09: Global CNS disorders therapeutics market 2015-2020 ($ billions)
Exhibit 10: Impact of drivers and challenges on global CNS disorders therapeutics market
Exhibit 11: Five forces analysis
Exhibit 12: Global CNS disorders therapeutics market: Segmentation by application (2015-2020)
Exhibit 13: Global CNS disorders therapeutics market: Segmentation by type of disease 2015
Exhibit 14: Global CNS disorders therapeutics market segmentation: Growth cycle analysis
Exhibit 15: Global depression drugs market 2015-2020 ($ billions)
Exhibit 16: Opportunity analysis of global depression drugs market
Exhibit 17: Global MS drugs market 2015-2020 ($ billions)
Exhibit 18: Opportunity analysis of global MS drugs market
Exhibit 19: Global schizophrenia drugs market 2015-2020 ($ billions)
Exhibit 20: Opportunity analysis of global schizophrenia drugs market
Exhibit 21: Global bipolar disorder therapeutics market 2015-2020 ($ billions)
Exhibit 22: Opportunity analysis of global bipolar disorder therapeutics market
Exhibit 23: Population aged 60 years and above in millions (1950-2050)
Exhibit 24: Global AD drugs market 2015-2020 ($ billions)
Exhibit 25: Opportunity analysis of global AD drugs market
Exhibit 26: Global epilepsy drugs market 2015-2020 ($ billions)
Exhibit 27: Percentage share of marketed antiepileptic drugs based on mechanism of action
Exhibit 28: Opportunity analysis of global epilepsy drugs market
Exhibit 29: Global PD drugs market 2015-2020 ($ billions)
Exhibit 30: Opportunity analysis of global PD drugs market
Exhibit 31: Global CNS disorders therapeutics market: Geography outlook (2015-2020)
Exhibit 32: Global CNS disorders therapeutics market: Geography outlook 2015
Exhibit 33: Global CNS disorders therapeutics market segmentation by geography: Market growth lifecycle analysis 2015
Exhibit 34: Global CNS disorders market revenue/growth outlook in different countries/regions 2015
Exhibit 35: Global CNS disorders therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 36: Opportunity analysis of CNS disorders therapeutics market in Americas
Exhibit 37: Projected prevalence rates of AD in Americas (2010-2050) (millions)
Exhibit 38: CNS disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 39: Percentage share of CNS disorders therapeutics market in Americas by geography 2015
Exhibit 40: Opportunity analysis of CNS disorders therapeutics market in EMEA
Exhibit 41: CNS disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 42: Opportunity analysis of CNS disorders therapeutics market in APAC
Exhibit 43: CNS disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 44: Few of the late-stage mAbs under development for various CNS disorders
Exhibit 45: Impact of drivers
Exhibit 46: Common disorders that co-exist with bipolar disorder
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Impact of trends on global CNS disorders therapeutics market
Exhibit 49: Planned clinical trials of iPS cell-based therapies
Exhibit 50: Position of key vendors in the global CNS disorders therapeutics market 2015
Exhibit 51: Geographical presence of key vendors
Exhibit 52: Company portfolio analysis in global CNS disorders therapeutics market 2016-2020
Exhibit 53: GlaxoSmithKline: Profile
Exhibit 54: GlaxoSmithKline: Sales of top-selling CNS drugs ($ millions)
Exhibit 55: GlaxoSmithKline: Metrics analysis
Exhibit 56: GlaxoSmithKline: Growth strategy matrix
Exhibit 57: GlaxoSmithKline: Opportunity assessment
Exhibit 58: Pfizer: Profile
Exhibit 59: Sales of CNS drugs ($ millions)
Exhibit 60: Pfizer: Metrics analysis
Exhibit 61: Pfizer: Growth strategy matrix
Exhibit 62: Pfizer: Opportunity assessment
Exhibit 63: Eli Lilly: Profile
Exhibit 64: Eli Lilly: Sales of top-selling CNS drugs ($ millions)
Exhibit 65: Eli Lilly: Metrics analysis
Exhibit 66: Eli Lilly: Growth strategy matrix
Exhibit 67: Eli Lilly: Opportunity assessment
Exhibit 68: Janssen Pharmaceuticals: Profile
Exhibit 69: Janssen Pharmaceuticals: Sales of CNS drugs ($ millions)
Exhibit 70: Janssen Pharmaceuticals: Metrics analysis
Exhibit 71: Janssen Pharmaceuticals: Growth strategy matrix
Exhibit 72: Janssen Pharmaceuticals: Opportunity assessment
Exhibit 73: Novartis: Profile
Exhibit 74: Novartis: Sales of few major CNS drugs ($ millions)
Exhibit 75: Novartis: Metrics analysis
Exhibit 76: Novartis growth strategy matrix
Exhibit 77: Novartis: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AB Science
  • Auspex Pharmaceuticals
  • Euthymics
  • Kyowa Hakko Kirin
  • Opexa
  • Shire
  • MORE
New Report Released: – Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020

The author of the report recognizes the following companies as the key players in the global central nervous system (CNS) disorders therapeutics market: GlaxoSmithKline, Pfizer, Eli Lilly, Janssen Pharmaceuticals, and Novartis.

Other Prominent Vendors in the market are: AB Science, AbbVie, Abital Pharma, Acorda Therapeutics, Active Biotech, Adamas Pharmaceuticals, Addex Therapeutics, Akorn, Alcobra, Alexza Pharmaceuticals, Alkermes, Amarantus, Aprecia Pharmaceuticals, Archer Pharmaceuticals, Astellas, AstraZeneca, Aurobindo Pharma, Auspex Pharmaceuticals, Avanir Pharmaceuticals, Biscayne Pharmaceuticals, Boehringer Ingelheim, Cerecor, Concordia, Convergence Pharmaceuticals, Curemark, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, Dart NeuroScience, Delpor, Desitin Arzneimittel, D-Pharm, Edgemont Pharmaceuticals, Endo International, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre-Kramer Pharmaceuticals, Forum Pharmaceuticals, Gedeon Richter, Glenmark, Grupo Ferrer Internacional, GW Pharmaceuticals, H. Lundbeck, Hisamitsu, Impax, Insero Health, INSYS Therapeutics, Intellipharmaceutics, Intra-Cellular Therapies, Ipsen, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Lupin, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda AB, Merck, Mitsubishi Tanabe, MSI Methylation Sciences, Mylan, Naurex, Neuralstem, Neurelis , Neurovance, Nobelpharma, Noven Pharmaceuticals, Omeros, Opexa, Opko Health, Orion, Ophelia Pharmaceutical, Otsuka Pharmaceuticals, Palobiofarma, Par Pharmaceuticals, Pierre Fabre, Pierre Fabre, Prana Biotechnology, Raptor Pharmaceutical, Reviva Pharmaceuticals , SAGE Therapeutics, Sanofi, SciFlour, Sedor Pharmaceuticals, Shire, Siena Biotech, SK Biopharmaceuticals, SOM Biotech, Somerset Pharmaceuticals, STADA Arzneimittel, Sun Pharmaceuticalc, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Suven, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Tris Pharma, Turing Pharmaceuticals, UCB, US WorldMeds, Valeant Pharmaceuticals, Zinfandel Pharmaceuticals, and Zogenix.

Commenting on the report, an analyst from the research team said: “One of the key trends for market growth will be popularity of me-too drugs. Owing to the high cost of development of new drugs, most pharmaceutical companies have been working on developing me-too drugs. A subtle molecular change is carried out in existing compounds to overcome the cost barrier. A me-too drug is a drug with a MOA similar to its predecessor drugs already present in the market. All selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors can be categorized as me-too drugs. Moreover, recently approved drugs for the treatment of depression are generally me-too drugs. Some of the prime examples of me-too drugs are desvenlafaxine (Pristiq), serotonin-norepinephrine reuptake inhibitor, and escitalopram (Lexapro) — a selective serotonin reuptake inhibitor, Pristiq — main metabolite of Effexor and Lexapro, which is the derivative of citalopram (Celexa).”

According to the report, high growth potential of mAbs will be a key driver for market growth. The understanding of a disease at the molecular level increases the development and use of biologics in the treatment. Biologics have a high affinity toward specific disease cells. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals. They will continue to out-perform pharmaceuticals in terms of product sales, as there is an increasing need for effective treatment options. Biologics that treat musculoskeletal disorders are made from proteins. Their MOA is inhibiting the action of key chemicals or cells involved in the nervous system. Few of the mAbs used to treat CNS disorders are natalizumab, daclizumab, and alemtuzumab. Other than these mAbs, many are in various stages of the pipeline for the treatment of CNS disorders.

Further, the report states that the activities of the brain are continuously monitored by RNS system, and when any patterns that could lead to seizures are detected, the neurostimulator sends brief impulses and disrupts the abnormal brain activity. In addition, Medtronic developed Medtronic deep brain stimulation (DBS) therapy as an adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. Also, NeuroSigma is under the Phase III development of external trigeminal nerve stimulation (eTNS) for epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox-Gastaut syndrome (LGS), and traumatic brain injury (TBI). The rise in research activities in the development of these devices along with their adoption for the treatment of seizures will act as a challenge for the global CNS disorders therapeutics market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- -  GlaxoSmithKline
-  Pfizer
-  Eli Lilly
-  Janssen Pharmaceuticals
-  AB Science
-  AbbVie
-  Abital Pharma
-  Acorda Therapeutics
-  Active Biotech
-  Adamas Pharmaceuticals
-  Addex Therapeutics
-  Akorn
-  Alcobra
-  Alexza Pharmaceuticals
-  Alkermes
-  Amarantus
-  Aprecia Pharmaceuticals
-  Archer Pharmaceuticals
-  Astellas
-  AstraZeneca
-  Aurobindo Pharma
-  Auspex Pharmaceuticals
-  Avanir Pharmaceuticals
-  Biscayne Pharmaceuticals
-  Boehringer Ingelheim
-  Cerecor
-  Concordia
-  Convergence Pharmaceuticals
-  Curemark
-  CURx Pharmaceuticals
-  Dainippon Sumitomo Pharma
-  Dart NeuroScience
-  Delpor
-  Desitin Arzneimittel
-  D-Pharm
-  Edgemont Pharmaceuticals
-  Endo International
-  E-Therapeutics
-  Euthymics
-  Evotec
-  F. Hoffmann-La Roche
-  Fabre-Kramer Pharmaceuticals
-  Forum Pharmaceuticals
-  Gedeon Richter
-  Glenmark
-  Grupo Ferrer Internacional
-  GW Pharmaceuticals
-  H. Lundbeck
-  Hisamitsu
-  Impax
-  Insero Health
-  INSYS Therapeutics
-  Intellipharmaceutics
-  Intra-Cellular Therapies
-  Ipsen
-  Kyowa Hakko Kirin
-  Ligand Pharmaceuticals
-  Lupin
-  MarcoPolo Pharmaceuticals
-  Marinus Pharmaceuticals
-  Meda AB
-  Merck
-  Mitsubishi Tanabe
-  MSI Methylation Sciences
-  Mylan
-  Naurex
-  Neuralstem
-  Neurelis
-  Neurovance
-  Nobelpharma
-  Noven Pharmaceuticals
-  Omeros
-  Opexa
-  Opko Health
-  Orion
-  Ophelia Pharmaceutical
-  Otsuka Pharmaceuticals
-  Palobiofarma
-  Par Pharmaceuticals
-  Pierre Fabre
-  Pierre Fabre
-  Prana Biotechnology
-  Raptor Pharmaceutical
-  Reviva Pharmaceuticals
-  SAGE Therapeutics
-  Sanofi
-  SciFlour
-  Sedor Pharmaceuticals
-  Shire
-  Siena Biotech
-  SK Biopharmaceuticals
-  SOM Biotech
-  Somerset Pharmaceuticals
-  STADA Arzneimittel
-  Sun Pharmaceuticalc
-  Sunovion Pharmaceuticals
-  Supernus Pharmaceuticals
-  Suven
-  Takeda Pharmaceuticals
-  Teva Pharmaceuticals
-  Torrent Pharmaceuticals
-  Tris Pharma
-  Turing Pharmaceuticals
-  UCB
-  US WorldMeds
-  Valeant Pharmaceuticals
-  Zinfandel Pharmaceuticals
-  Zogenix
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll